1. Home
  2. KLRS vs WAVE Comparison

KLRS vs WAVE Comparison

Compare KLRS & WAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • WAVE
  • Stock Information
  • Founded
  • KLRS 2019
  • WAVE 2011
  • Country
  • KLRS United States
  • WAVE Israel
  • Employees
  • KLRS N/A
  • WAVE N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • WAVE Electric Utilities: Central
  • Sector
  • KLRS Health Care
  • WAVE Utilities
  • Exchange
  • KLRS Nasdaq
  • WAVE Nasdaq
  • Market Cap
  • KLRS 46.0M
  • WAVE 40.3M
  • IPO Year
  • KLRS N/A
  • WAVE 2021
  • Fundamental
  • Price
  • KLRS $4.78
  • WAVE $7.42
  • Analyst Decision
  • KLRS Strong Buy
  • WAVE Strong Buy
  • Analyst Count
  • KLRS 3
  • WAVE 1
  • Target Price
  • KLRS $21.50
  • WAVE $15.00
  • AVG Volume (30 Days)
  • KLRS 107.9K
  • WAVE 36.3K
  • Earning Date
  • KLRS 11-13-2025
  • WAVE 11-11-2025
  • Dividend Yield
  • KLRS N/A
  • WAVE N/A
  • EPS Growth
  • KLRS N/A
  • WAVE N/A
  • EPS
  • KLRS N/A
  • WAVE N/A
  • Revenue
  • KLRS N/A
  • WAVE $168,000.00
  • Revenue This Year
  • KLRS N/A
  • WAVE $203.57
  • Revenue Next Year
  • KLRS N/A
  • WAVE $160.00
  • P/E Ratio
  • KLRS N/A
  • WAVE N/A
  • Revenue Growth
  • KLRS N/A
  • WAVE N/A
  • 52 Week Low
  • KLRS $2.14
  • WAVE $4.41
  • 52 Week High
  • KLRS $23.69
  • WAVE $17.63
  • Technical
  • Relative Strength Index (RSI)
  • KLRS 47.17
  • WAVE 44.14
  • Support Level
  • KLRS $4.67
  • WAVE $6.76
  • Resistance Level
  • KLRS $5.10
  • WAVE $7.97
  • Average True Range (ATR)
  • KLRS 0.41
  • WAVE 0.48
  • MACD
  • KLRS -0.03
  • WAVE -0.06
  • Stochastic Oscillator
  • KLRS 39.41
  • WAVE 42.74

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About WAVE Eco Wave Power Global AB (publ)

Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.

Share on Social Networks: